Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson's disease

Neuroscience

Volumn 284, Issue , 2015, Pages 234-246

  You, L H ^a   Li, F ^a   Wang, L ^a   Zhao, S E ^a,c   Wang, S M ^a   Zhang, L L ^b   Zhang, L H ^a   Duan, X L ^a   Yu, P ^a   Chang, Y Z ^a  

^a HEBEI NORMAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF APPLIED PHYSICS   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Brain iron; Ceruloplasmin knockout mouse; Parkinson's disease; Substantia nigra

Indexed keywords

CASPASE 3; CERULOPLASMIN; DEFEROXAMINE; FERRIC AMMONIUM CITRATE; IRON; PROTEIN BAX; PROTEIN BCL 2; ANTIPARKINSON AGENT; BAX PROTEIN, MOUSE; BCL2 PROTEIN, MOUSE; CASP3 PROTEIN, MOUSE; FERRIC ION; QUATERNARY AMMONIUM DERIVATIVE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; COORDINATION DISORDER; DISEASE EXACERBATION; DOPAMINERGIC NERVE CELL; IRON OVERLOAD; IRON STORAGE; MALE; MOTOR DYSFUNCTION; MOUSE; MPTP-INDUCED PARKINSONISM; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; BAGG ALBINO MOUSE; BRAIN; DEFICIENCY; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; MPTP POISONING; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BRAIN; CASPASE 3; CERULOPLASMIN; DEFEROXAMINE; DOPAMINERGIC NEURONS; FERRIC COMPOUNDS; IRON; MALE; MICE, INBRED BALB C; MICE, KNOCKOUT; MPTP POISONING; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUATERNARY AMMONIUM COMPOUNDS; TYROSINE 3-MONOOXYGENASE;

EID: 84908294565     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.09.071     Document Type: Article

References (41)

1. Ayton S., Lei P., Duce J.A., Wong B.X., Sedjahtera A., Adlard P.A., Bush A.I., Finkelstein D.I. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann Neurol 2013, 73:554-559.
2. Berg D., Hochstrasser H., Schweitzer K.J., Riess O. Disturbance of iron metabolism in Parkinson's disease - ultrasonography as a biomarker. Neurotox Res 2006, 9:1-13.
3. de Lau L.M., Giesbergen P.C., de Rijk M.C., Hofman A., Koudstaal P.J., Breteler M.M. Incidence of Parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004, 63:1240-1244.
4. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., Marsden C.D. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987, 2:1219-1220.
5. Driver J.A., Logroscino G., Gaziano J.M., Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009, 72:432-438.
6. Flaten T.P., Aaseth J., Andersen O., Kontoghiorghes G.J. Iron mobilization using chelation and phlebotomy. J Trace Elem Med Biol 2012, 26:127-130.
7. Golstein P. Controlling cell death. Science (New York, NY) 1997, 275:1081-1082.
8. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., Moller A., Nielsen K., Nyengaard J.R., Pakkenberg B., et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988, 96:857-881.
9. Han J., Day J.R., Thomson K., Connor J.R., Beard J.L. Iron deficiency alters H- and L-ferritin expression in rat brain. Cell Mol Biol (Noisy-le-grand) 2000, 46:517-528.
10. Hellman N.E., Gitlin J.D. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002, 22:439-458.
11. Hoepken H.H., Korten T., Robinson S.R., Dringen R. Iron accumulation, iron-mediated toxicity and altered levels of ferritin and transferrin receptor in cultured astrocytes during incubation with ferric ammonium citrate. J Neurochem 2004, 88:1194-1202.
12. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann Neurol 1998, 44:S72-84.
13. Jeong S.Y., David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 2003, 278:27144-27148.
14. Jeong S.Y., David S. Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J Neurosci 2006, 26:9810-9819.
15. Jiang H., Li L.J., Wang J., Xie J.X. Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra. Exp Neurol 2008, 212:532-537.
16. Jiang H., Song N., Wang J., Ren L.Y., Xie J.X. Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra. Neurochem Int 2007, 51:32-36.
17. Junxia X., Hong J., Wenfang C., Ming Q. Dopamine release rather than content in the caudate putamen is associated with behavioral changes in the iron rat model of Parkinson's disease. Exp Neurol 2003, 182:483-489.
18. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003, 37:899-909.
19. Ke Y., Chang Y.Z., Duan X.L., Du J.R., Zhu L., Wang K., Yang X.D., Ho K.P., Qian Z.M. Age-dependent and iron-independent expression of two mRNA isoforms of divalent metal transporter 1 in rat brain. Neurobiol Aging 2005, 26:739-748.
20. Ke Y., Qian Z. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2003, 2:246-253.
21. Kim T.I., Lee Y.K., Park S.G., Choi I.S., Ban J.O., Park H.K., Nam S.Y., Yun Y.W., Han S.B., Oh K.W., Hong J.T. l-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. Free Radic Biol Med 2009, 47:1601-1610.
22. Masaki T., Yoshimatsu H., Chiba S., Watanabe T., Sakata T. Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 2001, 50:376-384.
23. Miyajima H., Nishimura Y., Mizoguchi K., Sakamoto M., Shimizu T., Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987, 37:761-767.
24. Mounsey R.B., Teismann P. Chelators in the treatment of iron accumulation in Parkinson's disease. Int J Cell Biol 2012, 2012:983245.
25. Noyce A.J., Bestwick J.P., Silveira-Moriyama L., Hawkes C.H., Giovannoni G., Lees A.J., Schrag A. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012, 72:893-901.
26. Olivieri S., Conti A., Iannaccone S., Cannistraci C.V., Campanella A., Barbariga M., Codazzi F., Pelizzoni I., Magnani G., Pesca M., Franciotta D., Cappa S.F., Alessio M. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci 2011, 31:18568-18577.
27. Patel B.N., Dunn R.J., Jeong S.Y., Zhu Q., Julien J.P., David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci 2002, 22:6578-6586.
28. Rausch W.D., Hirata Y., Nagatsu T., Riederer P., Jellinger K. Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J Neurochem 1988, 50:202-208.
29. Saijo K., Winner B., Carson C.T., Collier J.G., Boyer L., Rosenfeld M.G., Gage F.H., Glass C.K. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137:47-59.
30. Sengstock G.J., Olanow C.W., Menzies R.A., Dunn A.J., Arendash G.W. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res 1993, 35:67-82.
31. Shao W., Zhang S.Z., Tang M., Zhang X.H., Zhou Z., Yin Y.Q., Zhou Q.B., Huang Y.Y., Liu Y.J., Wawrousek E., Chen T., Li S.B., Xu M., Zhou J.N., Hu G., Zhou J.W. Suppression of neuroinflammation by astrocytic dopamine D2 receptors via alphaB-crystallin. Nature 2013, 494:90-94.
32. Shi Z.H., Nie G., Duan X.L., Rouault T., Wu W.S., Ning B., Zhang N., Chang Y.Z., Zhao B.L. Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamine-induced dopaminergic cell damage: implication for neuroprotection in Parkinson's disease. Antioxid Redox Signal 2010, 13:783-796.
33. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., Youdim M.B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988, 74:199-205.
34. van Gelder W., Huijskes-Heins M.I., Cleton-Soeteman M.I., van Dijk J.P., van Eijk H.G. Iron uptake in blood-brain barrier endothelial cells cultured in iron-depleted and iron-enriched media. J Neurochem 1998, 71:1134-1140.
35. Wang J., Xu H.M., Yang H.D., Du X.X., Jiang H., Xie J.X. Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins. Neurochem Int 2009, 54:43-48.
36. Wang S.M., Fu L.J., Duan X.L., Crooks D.R., Yu P., Qian Z.M., Di X.J., Li J., Rouault T.A., Chang Y.Z. Role of hepcidin in murine brain iron metabolism. Cell Mol Life Sci 2010, 67:123-133.
37. Wu W.S., Zhao Y.S., Shi Z.H., Chang S.Y., Nie G.J., Duan X.L., Zhao S.M., Wu Q., Yang Z.L., Zhao B.L., Chang Y.Z. Mitochondrial ferritin attenuates beta-amyloid-induced neurotoxicity: reduction in oxidative damage through the Erk/P38 mitogen-activated protein kinase pathways. Antioxid Redox Signal 2013, 18:158-169.
38. Yu P., Chang Y.Z., Miao W., Wang S.M., Cui R., Qian Z.M., Ke Y., Duan X.L. Effects of intracerebroventricular injection of iron dextran on the iron concentration and divalent metal transporter 1 expression in the caudate putamen and substantia nigra of rats. Anat Rec (Hoboken, NJ: 2007) 2009, 292:225-233.
39. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004, 5:863-873.
40. Zhang J., Zhang Y., Wang J., Cai P., Luo C., Qian Z., Dai Y., Feng H. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res 2010, 1330:124-130.
41. Zheng T.S., Hunot S., Kuida K., Momoi T., Srinivasan A., Nicholson D.W., Lazebnik Y., Flavell R.A. Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. Nat Med 2000, 6:1241-1247.